Online citations, reference lists, and bibliographies.
← Back to Search

An Unusually Large Pleural Mesothelioma With An Outstanding Clinical Response And Long Lasting Survival: A Case Report And Literature Review

N. Zilembo, M. Vitali, F. Pietrantonio, M. Platania, M. Del Vecchio, E. Bajetta
Published 2010 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Malignant pleural mesothelioma is a neoplasm characterized by an increasing incidence and poor prognosis. When surgical treatment cannot be performed, systemic chemotherapy remains the main therapeutic option. Here we report the case of a 41-year-old female patient with epithelioid malignant pleural mesothelioma who was treated with carboplatin and pemetrexed despite her critical condition. She showed an impressive response to this first-line chemotherapy and, after disease progression, to further chemotherapy with gemcitabine and vinorelbine. She is still alive, with unexpectedly long-lasting survival. Free full text available at
This paper references
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM)
T. Karrison (2007)
C5-06: Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients with malignant mesothelioma
H. Kindler (2007)
Inhibition of PDGF receptor signaling in tumor stroma enhances antitumor effect of chemotherapy.
K. Pietras (2002)
Phase I and Pharmacokinetic Study of Imatinib Mesylate (Gleevec) and Gemcitabine in Patients with Refractory Solid Tumors
Y. Ali (2007)
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study.
M. Byrne (1999)
The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.
J. Stebbing (2009)
Pemetrexed Maintenance Therapy in Patients with Malignant Pleural Mesothelioma
D. P. M. van den Bogaert (2006)
Malignant pleural mesothelioma: a comprehensive review.
R. Ismail-Khan (2006)
Therapeutic outcome according to histologic subtype in 121 patients with malignant pleural mesothelioma.
G. Ceresoli (2001)
Gemcitabine and vinorelbine in pemetrexed‐pretreated patients with malignant pleural mesothelioma
P. Zucali (2008)
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
Palliative Treatment of Malignant Pleural Effusions
D. Horn (2010)
Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials
G. Ceresoli (2008)
Malignant pleural mesothelioma: clinicopathologic and survival characteristics in a consecutive series of 394 patients.
P. Borasio (2008)
Erlotinib plus bevacizumab in previously treated patients with malignant pleural mesothelioma
D. Jackman (2008)
Poplin EA: Phase I and pharmacokinetic study of imatinib mesylate (Gleevec®) and gemcitabine in patients with refractory solid tumors
Y Ali (2007)
[Malignant pleural mesothelioma].
Q. Kong (1983)
Mesothe - lioma review
AS Tsao

Semantic Scholar Logo Some data provided by SemanticScholar